Insider Buying: Antares Pharma Director Acquires 5,000 Shares of Stock (ATRS)
Antares Pharma (NASDAQ:ATRS) Director Robert P. Roche, Jr. purchased 5,000 shares of Antares Pharma stock on the open market in a transaction dated Wednesday, August 13th. The stock was purchased at an average cost of $1.96 per share, for a total transaction of $9,800.00. Following the purchase, the director now directly owns 28,172 shares in the company, valued at approximately $55,217. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link.
Shares of Antares Pharma (NASDAQ:ATRS) opened at 2.14 on Friday. Antares Pharma has a 52 week low of $1.87 and a 52 week high of $5.15. The stock has a 50-day moving average of $2.27 and a 200-day moving average of $3.24. The company’s market cap is $279.2 million.
Antares Pharma (NASDAQ:ATRS) last announced its earnings results on Thursday, August 7th. The company reported ($0.07) EPS for the quarter, meeting the Thomson Reuters consensus estimate of ($0.07). The company had revenue of $6.30 million for the quarter, compared to the consensus estimate of $6.43 million. On average, analysts predict that Antares Pharma will post $-0.24 earnings per share for the current fiscal year.
Antares Pharma, Inc (NASDAQ:ATRS) is a pharma company that focuses on self-injection pharmaceutical products and technologies and topical gel-based products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.